NCT05828225招募中1 期
A Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Refractory Myasthenia Gravis
Zhejiang University1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2023年4月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicity (DLT)
研究概览
简要总结
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD19 CAR-T therapy for patients with refractory myasthenia gravis, and to evaluate the pharmacokinetics of CD19 CAR-T in patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 and gender unlimited；
- •Confirmed as refractory myasthenia gravis with AchR antibody positive and accord one of the following three conditions
- •Repeated electrical stimulation suggests neuromuscular conduction deficits；
- •Tensilon test and neostigmine test positive;
- •The doctor judged that the symptoms of MG improved after treatment with oral cholinease inhibitors;
- •Consistent with the clinical classification of MGFA myasthenia gravis IIa-IVb (including IIa，IIb，IIIa， IIIb， IVa，IVb)
- •The baseline MG-ADL score ≥5 and the musculi oculi related score< 50 ；
- •Baseline QMG score>11;
- •Regular treatment with poor efficacy and/or lack of effective treatment means that there is still recurrence or exacerbation after treatment with conventional hormones, immunosuppressants (such as azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A, cyclophosphamide, etc.) or rituximab；
- •The estimated survival time is more than 12 weeks;
- •Women of childbearing age who have negative urine pregnancy test before medication administration and agree to take effective contraceptive measures during the trial period until the last follow-up.
排除标准
- •Epilepsy history or other central nervous system disease;
- •During the screening visit, the patient's thymectomy was less than 12 months or thymectomy was necessary during the study period or thymic radiation therapy ;
- •Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythm ia in the past;
- •Pregnant (or lactating) women;
- •Patients with severe active infections;
- •Active infection of hepatitis B virus or hepatitis C virus;
- •Systemic steroids have used in the 4 weeks before participating in the treatment (except recently or currently using inhaled steroids);
- •Those who have used any gene therapy products before;
- •The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
- •Serum creatinine > 2.5mg/dl or ALT / AST > 3 times ULN or bilirubin > 2.0 mg /dl;
- •Those who suffer from other uncontrolled diseases are not suitable to join the study;
- •HIV infection;
- •Any situation that the researchers believe may increase the risk of patients or interfere with the test results.
研究组 & 干预措施
Treatment Group
Experimental
Myasthenia Gravis
干预措施: CD19 CAR-T cells injection (Drug)
结局指标
主要结局
Dose-limiting toxicity (DLT)
时间窗: Baseline up to 28 days after CD19 CAR T-cells infusion
Adverse events assessed according to NCI-CTCAE v5.0 criteria
Maximum tolerable dose
时间窗: From date of initial treatment to Day 28 post CD19 CAR-T infusion.
Maximum tolerable dose
Incidence of treatment-emergent adverse events (TEAEs)
时间窗: Up to 90 days after CD19 CAR T-cells infusion
Incidence of treatment-emergent adverse events \[Safety and Tolerability\]
次要结局
- Changes in serum AchR antibody titer(days 7, 14, 21, 28 and 90)
- MG-QOL15 scale(Baseline up to 28 days after CD19 CAR T-cells infusion)
- MG-activities of daily living profile (MG-ADL)(Baseline up to 28 days after CD19 CAR T-cells infusion)
- Myasthenia Gravis Composite Scale (MGC)(Baseline up to 28 days after CD19 CAR T-cells infusion)
- MG-activities of daily living profile (QMG)(Baseline up to 28 days after CD19 CAR T-cells infusion)
研究者
He Huang
Clinical Professor
Zhejiang University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis OpticaNeuromyelitis OpticaNCT05828212Zhejiang University9
Unknown
早期 1 期
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell TransplantationAdult B Acute Lymphoblastic LeukemiaNCT04626726Hebei Senlang Biotechnology Inc., Ltd.50
Unknown
早期 1 期
CAR-T Cells in Treating Patients With Relapsed or Refractory NHLRefractory Indolent Adult Non-Hodgkin LymphomaNCT04626739Hebei Senlang Biotechnology Inc., Ltd.100
Unknown
1 期
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver MalignancyCarcinoma, HepatocellularPancreatic Cancer MetastaticColorectal Cancer MetastaticNCT02959151Shanghai GeneChem Co., Ltd.20
招募中
1 期
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid TumorsAdvanced Malignant Solid TumorsNCT06728189Peking University Cancer Hospital & Institute13